Trial Profile
A Phase 2 Study of LY2606368 in Patients With Extensive Stage Disease Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Prexasertib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company; Eli Lilly and Company (India) Pvt. Ltd
- 12 Mar 2020 Planned number of patients changed from 131 to 133.
- 02 May 2019 Status changed from active, no longer recruiting to completed.
- 08 Feb 2019 Planned number of patients changed from 116 to 131.